Jacobus snags pediatric approval of rare autoimmune disease drug based on adult efficacy data

With the pediatric approval of Jacobus' Ruzurgi amifampridine to treat Lambert-Eaton myasthenic syndrome (LEMS) based on clinical data in adults, FDA could be signaling a shift towards greater acceptance of pediatric extrapolation.

Last year, FDA penned draft

Read the full 362 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE